title: First-line treatment of chronic myeloid leukaemia.
abstract: Since the introduction of imatinib just over a decade ago, there has been a dramatic change in the treatment and prognosis of early chronic phase chronic myeloid Leukaemia (CML). This review article focuses on recent advances, culminating in the approval of nilotinib by the US Food and Drug Administration for the treatment of adult patients with newly diagnosed CML in the chronic phase.
authors.forename: Michael
authors.initials: M
authors.lastname: O'Dwyer
keywords: CML; early chronic phase; treatment; tyrosine kinase inhibitor
references.citation: Leukemia. 2008 Jun;22(6):1200-6
references.pmid: 18401416
references.citation: Blood. 2009 Jun 18;113(25):6315-21
references.pmid: 19369233
references.citation: Nature. 2009 Apr 16;458(7240):904-8
references.pmid: 19212321
references.citation: J Clin Oncol. 2009 Dec 10;27(35):6041-51
references.pmid: 19884523
references.citation: Leukemia. 2010 Jun;24(6):1105-12
references.pmid: 20445577
references.citation: Cancer Cell. 2010 Jul 13;18(1):74-87
references.pmid: 20609354
references.citation: J Clin Oncol. 2010 Jan 20;28(3):424-30
references.pmid: 20008622
references.citation: Semin Hematol. 2009 Apr;46(2 Suppl 3):S27-33
references.pmid: 19621547
references.citation: N Engl J Med. 2010 Jun 17;362(24):2251-9
references.pmid: 20525993
references.citation: N Engl J Med. 2010 Jun 17;362(24):2260-70
references.pmid: 20525995
references.citation: Blood. 2000 Nov 1;96(9):3195-9
references.pmid: 11050003
references.citation: Blood. 2007 Nov 15;110(10):3540-6
references.pmid: 17715389
references.citation: Blood. 2004 Apr 15;103(8):2873-8
references.pmid: 15070658
references.citation: Blood Rev. 2006 Jan;20(1):29-41
references.pmid: 16426942
references.citation: Blood. 2009 Dec 3;114(24):4933-8
references.pmid: 19822896
references.citation: Blood. 1999 Sep 1;94(5):1517-36
references.pmid: 10477676